17 Sep 2024 update: This is now the first of a 3-part newsletter series! See also part 2 (“R&D Implications: Global Burden of Disease is 28% Infectious!“) and part 3 (17 Sep 2024: “#AMRSOS! AMR could worsen, killing 39m during 2025-2050”). Dear All, There are days when it is hard to keep up! Not only
Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check
Dear All, Three bits of news you can use… First, when I wrote yesterday about the new Indian Priority Pathogen List (PPL), I said that it was similar to the WHO PPL list except for the addition of Staphylococcus epidermidis (and speculated that this relates to the role of S. epidermidis in neonatal sepsis). Well, it
Dear All, As has been discussed in recent newsletters (link), the UK National Institute for Health and Care Excellence (NICE) and NHS England launched a joint project July 2019 to test a payment model for antibiotic products, based on a product’s value to the NHS, rather than how much is used. This goal of the
Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and
Dear All, First, Nature published an excellent article entitled “The importance of antimicrobial resistance in medical mycology” by Gow et al. The first sentence of the introduction really packs a punch — “The age of antibiotics, spanning only 80 years, is now entering a period of progressive and widespread emergence of drug-resistant organisms that threaten to bring
Dear All, I’ve written before about the FORWARD Act, a bill introduced last year into Congress with the goal of supporting research in to treatment of endemic fungal diseases with a particular focus on coccidioidomycosis (*). It’s easy to see how this bill and the PASTEUR Act are mutually supportive … both seek to build
Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive
Dear All, Once again, we’re going to have a brief change from our usual programming with this newsletter. I hope you recognize the name Alan Carr … he is an analyst at Needham & Company (https://www.needhamco.com/) who writes regularly on the antibacterial pipeline. Go here for the most recent (14 Aug 20) newsletter on his summaries:
Dear All, I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City NY! The deadline to